1. Pink Sheet

Sponsors Aim To Avoid Confirmatory Trial Hurdles That Plagued Ocaliva In Primary Biliary Cholangitis

 
• By Sue Sutter

The FDA and sponsors of two new accelerated approval drugs for PBC have taken steps in study design, initiation and reporting transparency to ensure timely completion.

Hurdles
Sponsors of new PBC drugs are hoping to avoid some of the hurdles that plagued Ocaliva's confirmatory trial. • Source: Shutterstock

The US Food and Drug Administration and sponsors of two new accelerated approval drugs for primary biliary cholangitis appear to have taken steps to avoid some of the problems that tripped up the confirmatory trial for Intercept Pharmaceuticals, Inc.’s Ocaliva (obeticholic acid).

Key Takeaways

  • The confirmatory trial for Intercept’s Ocaliva began before accelerated approval, but was negatively impacted by safety-related labeling changes and the crossover to commercial drug.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Post-Marketing Regulation & Studies

More from Product Reviews

US FDA’s Rising First-Cycle Complete Response Rate Draws Congress’ Attention

 
• By Sue Sutter

The House Appropriations Committee wants an analysis of how issues that led to CRLs could have been resolved within the first review cycle and seeks an agency crackdown on counterfeit GLP-1 agonists.

‘Clean Sweep’ Of US CDC Vaccine Committee Puts Kennedy In Driver’s Seat

 
• By Bridget Silverman

With a 25-27 June meeting looming, HHS Secretary Robert F. Kennedy Jr. can fill all 17 spots on the CDC's Advisory Committee on Immunization Practices with people he says will "exercise independent judgment."

Infographic: Leqembi – A Geographical Comparison

 
• By Anabel Costa-Ferreira

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.